Disintegrin targeting of an αvβ3 integrin-over-expressing high-metastatic human osteosarcoma with echistatin inhibits cell proliferation, migration, invasion and adhesion in vitro

Oncotarget. 2016 Jul 19;7(29):46315-46320. doi: 10.18632/oncotarget.10111.

Abstract

The in vitro efficacy of the disintegrin echistatin was tested on a high-metastatic variant of 143B human osteosarcoma, 143B-LM4, which over-expresses αvβ3 integrin. Echistatin is an RGD cyclic peptide and an antagonist of αvβ3 integrin. In the present study, echistatin inhibited cell proliferation, migration, invasion, and adhesion of 143B-LM4 cells. 143B-LM4 cell proliferation decreased after treatment with echistatin in a time-dependent and dose-dependent manner (P <0.01). In vitro migration and invasion of 143B-LM4 cells were also inhibited by echistatin in a dose-dependent manner (P <0.01, respectively). Cell adhesion to vitronectin of 143B-LM4 cells was also inhibited by echistatin in a dose-dependent manner (P <0.01). These results suggest that αvβ3 integrin may be an effective target for osteosarcoma.

Keywords: echistatin; green fluorescent protein/red fluorescent protein; metastasis; osteosarcoma; αv β3 integrin.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Bone Neoplasms / pathology*
  • Cell Adhesion / drug effects
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Disintegrins / pharmacology
  • Humans
  • Integrin alphaVbeta3 / antagonists & inhibitors*
  • Intercellular Signaling Peptides and Proteins
  • Neoplasm Invasiveness / pathology
  • Osteosarcoma / pathology*
  • Peptides / pharmacology*

Substances

  • Antineoplastic Agents
  • Disintegrins
  • Integrin alphaVbeta3
  • Intercellular Signaling Peptides and Proteins
  • Peptides
  • echistatin